Lantern Pharma's AI-Based Drug Discovery and Development Targeting Cancer

Oncology drug development today is a perfect environment for Artificial Intelligence. Cancer treatment development is time consuming, costly, and high risk. This is a perfect problem area for Lantern Pharma’s approach to pharmaceutical biotechnology using machine learning and AI.

Lantern Pharma has a targeted, personalized approach to oncology drug development: RADR®
Lantern Pharma is a life science company leading the charge in advancing and accelerating the development of precision oncology therapeutics using A.I., genomics and machine learning.

RADR® is being continually improved by Lantern Pharma for the development of our drug portfolio and to pinpoint patient groups that can be best treated by our therapies and the therapies of our partners.

Lantern Pharma’s goal is straightforward: to vanquish, defeat, crush cancer. Towards this end, we are constantly pushing innovations in biotech A.I. and genetic oncology, so that we can create personalized cancer therapies and ensure the right patients get the right drug. We embrace the freedom to create and problem-solve to win this fight and accelerate the speed at which these treatments make it to market. Everything we do is focused on ending cancer.